Fig. 3From: Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyThe median value (95% CI bars) of MMDs percentual reduction in the last month of therapy in patients relapsing to < 50% response rate at F-UP1, F-UP2, F-UP3, and patients still responding at F-UP3 (Mann-Whitney U test)Back to article page